Incyclix Bio is advancing next-generation precision treatments to regain control of the cell cycle where aberrant proliferation is a fundamental driver of many cancers. We believe the CDK family is a rich source of of novel cancer targets worthy of drug development. Our team is applying its unsurpassed expertise and deep knowledge of CDK inhibitors to bring hope to people with advanced and resistant cancers.

Dysregulated kinase activity of specific CDK family members drives uncontrolled cellular proliferation – a hallmark of cancer. Recent advances in cancer treatment using selective CDK4/6 inhibitors has redefined the treatment of hormone receptor positive breast cancer patients. Unfortunately, many tumors rely on other CDK family members, such as CDK2, to drive uncontrolled proliferation thus necessitating the need for new therapeutic approaches beyond CDK4/6 to regain cell cycle control.

VISIT WEBSITE